Type 2 diabetes patients can significantly lower their risk for 10 obesity-related cancers if they take Ozempic instead of insulin to manage the disease, new research finds.
Type 2 diabetes patients can significantly lower their risk for 10 obesity-related cancers if they take Ozempic instead of insulin to manage the disease, new research finds.
The study included 1.65 million people with Type 2 diabetes who were prescribed insulin, metformin or an Ozempic-like drug between March 2005 and November 2018.
Type 2 diabetes — which affects more than 34 million Americans — occurs when the body doesn’t produce enough insulin or doesn’t use insulin well, resulting in high blood sugar.
Metformin, injectable insulin and drugs like Ozempic that mimic the appetite-suppressing hormone GLP-1 can help people with Type 2 diabetes control their blood sugar levels. Ozempic has been shown to cause greater weight loss than metformin, while weight gain is a common side effect of insulin therapy.
